STAB1 and neoplasm: This immune activation results in anti-tumor activity in mouse models10 and clinical benefit in patients with advanced solid tumors12 treated with a therapeutic humanized anti-CLEVER-1 IgG4 antibody (FP-1305, bexmarilimab).